Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01604590 : Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme
AgesMin: 18 Years Max: 80 Years
Inclusion Criteria:

- Age between 18 and 80 years of age

- Progressive glioblastoma patients who have been planned to receive bevacizumab

- Karnofsky Performance Status 50 or above (vd. Appendix A)

- Established pathologic diagnosis of glioblastoma

- Prior treatment with radiation and chemotherapy

- Neuroimaging progression of glioblastoma

- Able and willing to provide informed consent (or consent of a guardian)

Exclusion Criteria:

- Contraindication to MRI

- Contraindication to bevacizumab therapy

- Concurrent enrollment in other neuroimaging trials

- Prior therapy with bevacizumab

- Known hypersensitivity to MRI contrast

- Females who are nursing or pregnant
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557